ARVO 2020: Two-year anatomical outcomes of FAc in DME patients

June 25, 2020
Alex Delaney-Gesing


Victor Gonzalez, MD, speaks with Ophthalmology Times® David Hutton on the highlights of his presentation regarding "Two-year outcomes from the PALADIN Phase 4 study: Anatomic/functional changes and reduced treatment frequency associated with 0.19 mg of fluocinolone acetonide implant (FAc) with persistent or recurrent diabetic macular edema," during the 2020 Association for Research in Vision and Ophthalmology (ARVO) virtual meeting.

See more ARVO coverage here

Related Content:

ARVO | Clinical